Answer
Yes, cardiomyopathy with cardiac decompensation has been reported after marketing of decitabine (Dacogen), with some cases reversible after treatment discontinuation, dose reduction or corrective treatment.
Sources for this answer
- Dacogen 50 mg powder for concentrate for solution for infusion.(Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 16Document updated
Sources checked